Epitope-focused vaccine design against influenza A and B viruses.
Epitope-focused vaccine design against influenza A and B viruses. Curr Opin Immunol. 2016 Jun 22;42:83-90 Authors: Ren H, Zhou P Abstract The threat of influenza A and B variants via antigenic drift and emerging novel influenza A and B strains in the human population via antigenic shift has spurred research efforts to improve upon current seasonal influenza vaccines. In recent years, a wave of novel technological breakthroughs has lead to the identification of many broadly anti-influenza hemagglutinin (HA) monoclonal antibodies (mAbs) and the elucidation of the conserved epitopes recognized by these mAbs in both the head and the stem of HA as well as the mechanisms of inhibition. These discoveries along with an improved understanding of how the immune system responds to influenza infection and vaccination has spurred great efforts on stem-based cross-subtype ('universal') vaccine design as well as RBS-based HA subtype-specific vaccine design. PMID: 27343703 [PubMed - as supplied by publisher]
Funding Opportunity RFA-AI-20-003 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications to support development of promising universal influenza vaccine candidates that protect against both influenza A and B viruses.
The rapid spread of the coronavirus now called COVID-19 has sparked alarm worldwide. The World Health Organization (WHO) has declared a global health emergency, and many countries are grappling with a rise in confirmed cases. In the US, the Centers for Disease Control and Prevention (CDC) is advising people to be prepared for disruptions to daily life that will be necessary if the coronavirus spreads within communities. Below, we’re responding to a number of questions about COVID-19 raised by Harvard Health Blog readers. We hope to add further questions and update answers as reliable information becomes available. Do...
According to a Feb. 21Morbidity and Mortality Weekly Report from the CDC, the current influenza vaccine has been 45% effective overall against 2019-2020 seasonal influenza A and B viruses.
Okay, I'm not an epidemiologist or a virologist. But I do know something about those subjects, I'm a public health professor, and I am an expert in clinical communication and risk communication. So I'm going to offer some observations that I hope will help people keep this public health scare in proper perspective and maybe be of practical use.There are two important parameters we need to understand the risk caused by any communicable disease. I'm going to broadly say transmissibility, and the probability that exposure will lead to serious disease.We often see transmissibility represented as a single number, called R0 or &...
Publication date: July 2019Source: Biomedical and Environmental Sciences, Volume 32, Issue 7Author(s): Xue Ting FAN, Yun Long WANG, Qiu Dong SU, Feng QIU, Yao YI, Zhi Yuan JIA, Da Yan WANG, Kun QIN, Ye Ning ZOU, Sheng Li BI, Li Ping SHEN
CONCLUSION: An outreach program comprising of a means of taking vaccines to the population was a successful strategy to deliver influenza vaccines to high-risk populations. It needs to be considered in the full range of delivery models to improve influenza vaccine coverage, even in resource-rich settings. Implication for public health: Strategies reaching out to vulnerable populations are crucial to maximise vaccine uptake. PMID: 32101355 [PubMed - as supplied by publisher]
The quadrivalent version of Fluad was safe and effective against influenza strains included in the vaccine in multiple clinical studies with adults aged 65 years or older.News Alerts
ConclusionsThough the number of pro-vaccine posts increased, antivaccine posts remained more popular. The government agency may use an emotive personal family-oriented message to promote vaccination.
Immunotherapy,Volume 12, Issue 2, Page 151-159, February 2020.